Connection
Augusto Miravalle to Immunosuppressive Agents
This is a "connection" page, showing publications Augusto Miravalle has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.202 |
|
|
|
-
Miravalle AA, Katz J, Robertson D, Hayward B, Harlow DE, Lebson LA, Sloane JA, Bass AD, Fox EJ. CLICK-MS and MASTER-2 Phase IV?trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegener Dis Manag. 2021 04; 11(2):99-111.
Score: 0.552
-
Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Am J Manag Care. 2011 May; 17 Suppl 5 Improving:S154-60.
Score: 0.281
-
Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 Feb; 68(2):186-91.
Score: 0.270
-
Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol. 2011 Jun; 235(1-2):9-17.
Score: 0.069
-
Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
Score: 0.030